| 000 | 01356 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250513185534.0 | ||
| 264 | 0 | _c19990817 | |
| 008 | 199908s 0 0 eng d | ||
| 022 | _a0023-6764 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOz, H S | |
| 245 | 0 | 0 |
_aRat model for dual opportunistic pathogen prophylaxis: Cryptosporidium parvum and Pneumocystis carinii. _h[electronic resource] |
| 260 |
_bLaboratory animal science _cJun 1999 |
||
| 300 |
_a331-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCarbamates _xtherapeutic use |
| 650 | 0 | 4 |
_aCryptosporidiosis _xcomplications |
| 650 | 0 | 4 |
_aCryptosporidium parvum _xpathogenicity |
| 650 | 0 | 4 |
_aDexamethasone _xpharmacology |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aIleum _xdrug effects |
| 650 | 0 | 4 | _aImmunocompromised Host |
| 650 | 0 | 4 |
_aLung _xdrug effects |
| 650 | 0 | 4 |
_aNaphthoquinones _xtherapeutic use |
| 650 | 0 | 4 |
_aPneumocystis _xpathogenicity |
| 650 | 0 | 4 |
_aPneumonia, Pneumocystis _xcomplications |
| 650 | 0 | 4 |
_aProdrugs _xtherapeutic use |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 700 | 1 | _aHughes, W T | |
| 700 | 1 | _aRehg, J E | |
| 773 | 0 |
_tLaboratory animal science _gvol. 49 _gno. 3 _gp. 331-4 |
|
| 999 |
_c10361681 _d10361681 |
||